Clinical Trial Update: Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08) [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant trial (NEOTORCH-BREAST 08) is evaluating combining trastuzumab with toripalimab for HR-positive/HER2-low breast cancer; the study is curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Toripalimab (Toripalimab)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: First Affiliated Hospital of Zhejiang University | Conditions: HR Positive/HER2 Low Breast Cancer | Phase 2 | Status: RECRUITING